Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Gillett

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Advanced Nursing|July 9, 2025
The Impact of Gestational Trophoblastic Neoplasia Following the Completion of Treatment: A Descriptive Exploratory Qualitative StudyKam Singh, Clare Warnock, Sarah Rollins, et al.
The Journal of Reproductive Medicine|July 31, 2012
Initial presenting features in gestational trophoblastic neoplasia: does a decade make a difference?Stacey Killick, Jane Cook, Sarah Gillett, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|December 3, 2023
Patients' experience of menopausal symptoms post-chemotherapy treatment for gestational trophoblastic neoplasiaKam Singh, Jane Ireson, Sarah Rollins, et al.
The Journal of Reproductive Medicine|July 19, 2016
Evolution of a Teenage and Young Adult Service, in Sheffield, U.K., for Patients with Gestational Trophoblastic NeoplasiaSarah Gillett, Kam Singh, Jane Ireson, et al.
Neurology|September 12, 2014
ABO blood type, factor VIII, and incident cognitive impairment in the REGARDS cohortKristine S Alexander, Neil A Zakai, Sarah Gillett, et al.
The Journal of Reproductive Medicine|June 19, 2014
Evolution of a specialist gestational trophoblastic disease service with a major nursing component: the Sheffield, United Kingdom, experienceJane Ireson, Kamaljit Singh, Sarah Gillett, et al.
International Journal of Cancer|November 19, 2020
M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasiaKam Singh, Sarah Gillett, Jane Ireson, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Advanced Nursing|July 9, 2025
The Impact of Gestational Trophoblastic Neoplasia Following the Completion of Treatment: A Descriptive Exploratory Qualitative StudyKam Singh, Clare Warnock, Sarah Rollins, et al.
The Journal of Reproductive Medicine|July 31, 2012
Initial presenting features in gestational trophoblastic neoplasia: does a decade make a difference?Stacey Killick, Jane Cook, Sarah Gillett, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|December 3, 2023
Patients' experience of menopausal symptoms post-chemotherapy treatment for gestational trophoblastic neoplasiaKam Singh, Jane Ireson, Sarah Rollins, et al.
The Journal of Reproductive Medicine|July 19, 2016
Evolution of a Teenage and Young Adult Service, in Sheffield, U.K., for Patients with Gestational Trophoblastic NeoplasiaSarah Gillett, Kam Singh, Jane Ireson, et al.
Neurology|September 12, 2014
ABO blood type, factor VIII, and incident cognitive impairment in the REGARDS cohortKristine S Alexander, Neil A Zakai, Sarah Gillett, et al.
The Journal of Reproductive Medicine|June 19, 2014
Evolution of a specialist gestational trophoblastic disease service with a major nursing component: the Sheffield, United Kingdom, experienceJane Ireson, Kamaljit Singh, Sarah Gillett, et al.
International Journal of Cancer|November 19, 2020
M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasiaKam Singh, Sarah Gillett, Jane Ireson, et al.
Pageof 1